Open AccessEfficacy of Tramadol Extended-Release for Opioid Withdrawal
Author(s) -
Kelly E. Dunn,
D. Andrew Tompkins,
George E. Bigelow,
Eric C. Strain
Publication year - 2017
Publication title -
jama psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.531
H-Index - 365
eISSN - 2168-6238
pISSN - 2168-622X
DOI - 10.1001/jamapsychiatry.2017.1838
Subject(s) - buprenorphine , tramadol , medicine , opioid use disorder , placebo , anesthesia , analgesic , opioid , clonidine , acetaminophen , randomized controlled trial , naltrexone , receptor , alternative medicine , pathology
Opioid use disorder (OUD) is a significant public health problem. Supervised withdrawal (ie, detoxification) from opioids using clonidine or buprenorphine hydrochloride is a widely used treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom